The tweet was deleted by the author.
But we saved everything 🙂.
Lineage Cell Therapeutics is at the forefront of regenerative medicine, focusing on scalable, allogeneic cell therapies to restore lost function.
Their CEO, Culley, was recently featured by Xtalks, where the company highlighted its innovative approach to cell therapy. This method could revolutionize how we approach regenerative medicine by making therapies more accessible.
Allogeneic therapies, derived from a donor rather than a patient's own cells, hold promise for wide-scale application due to their scalability. As the field of regenerative medicine continues to grow, Lineage Cell Therapeutics is positioning itself as a leader in developing solutions to repair and regenerate tissues.
To learn more about their advancements, visit [the full article](https://t.co/DOx0AAjxSd).
These developments align with Lineage's ongoing engagement in the sector, notably highlighted when the company's CEO participated in the AAO Annual Meeting, as explored in discussions on executive leadership in ophthalmology. Further context on the company’s financial trajectory and strategic direction can also be found in their recent Q3 2025 results and business update, underscoring Lineage’s continued momentum in regenerative medicine.